XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Positive Results from Six-Month Phase 2 Trial of Mavorixafor in ...

Late-onset neutropenia (LON) is a common late adverse event after rituximab treatment. LON is defined as an unexplained absolute neutrophil count of ≤1.5 ×10 9 /l, starting from 4 weeks after ...

A joint FDA advisory committee on Tuesday overwhelming voted to eliminate the risk evaluation and mitigation strategy (REMS) ...

Mavorixafor durably and meaningfully elevated participants’ mean absolute neutrophil counts (ANC) Mavorixafor enabled substantial reductions in ...

An analysis of final data from the six-month study showed that once-daily oral mavorixafor durably and meaningfully increased participants’ mean absolute neutrophil counts (ANC). In addition ...

Two FDA panels were almost unanimous in their opinion that the agency should eliminate restrictions that psychiatrists and ...

On November 13, 2024, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) announced positive topline results from the Phase 2 trial of mavorixafor in patients with chronic neutropenia (CN). This was a six ...

An analysis of final data from the six-month study showed that once-daily oral mavorixafor durably and meaningfully increased participants’ mean absolute neutrophil counts (ANC). In addition, when ...